Erlotinib-associated severe bilateral recalcitrant keratouveitis after corneal EDTA chelation  by Zhou, Zimei et al.
lable at ScienceDirect
American Journal of Ophthalmology Case Reports 4 (2016) 1e3Contents lists avaiAmerican Journal of Ophthalmology Case Reports
journal homepage: http : / /www.ajocasereports .com/Case reportErlotinib-associated severe bilateral recalcitrant keratouveitis after
corneal EDTA chelation
Zimei Zhou, Kumar Sambhav, K.V. Chalam*
Department of Ophthalmology, University of Florida, College of Medicine, Jacksonville, FL, United Statesa r t i c l e i n f o
Article history:
Received 7 January 2016
Received in revised form
19 May 2016
Accepted 1 June 2016
Available online 3 June 2016
Keywords:
Erlotinib
Band keratopathy
Corneal chelation
Keratouveitis* Corresponding author. Department of Ophthalm
Jacksonville 580 W 8th Street, Tower 2, 3rd ﬂoor, Ja
States.
E-mail address: kvchalam@aol.edu (K.V. Chalam).
http://dx.doi.org/10.1016/j.ajoc.2016.06.003
2451-9936/© 2016 The Authors. Published by Elseviera b s t r a c t
Purpose: We report a case of erlotinib-associated severe recalcitrant bilateral keratouveitis after un-
eventful corneal ethylenediaminetetraacetic acid (EDTA) chelation in a patient with non-small cell lung
cancer (NSCLC); discontinuation of erlotinib led to complete resolution.
Observations: An elderly person presented with band keratopathy (BSK) of undetermined etiology in the
both eyes, associated with foreign body sensation and constant tearing. The patient was on oral erlotinib
treatment 150 mg PO daily for 1 year for NSCLC status post radiation therapy. Corneal EDTA chelation
was performed in both eyes under topical anesthesia for BSK. Four days after surgery, the patient pre-
sented with severe pain in both eyes. Slit lamp evaluation revealed 5 mm  7 mm epithelial defect with
clear margins in the right eye and 6  7 mm epithelial defect with thick central corneal inﬁltrate in the
left eye. Hypopyon was noticed in both eyes and intense inﬂammation obscured the details of anterior
segment. Intense antibiotic treatment was initiated. After discussion with the oncology services, oral
erlotinib was temporarily discontinued. This resulted in resolution of keratitis and hypopyon in both
eyes, within one week.
Conclusions: and importance: Systemic use of erlotinib suppresses local immunity, facilitates infection
and enhances inﬂammatory reaction in the eye. Clinicians should be cautious and plan any ocular
interventional treatment in collaboration with oncology team to prevent adverse outcomes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Erlotinib (Tarceva; Genetech Inc, San Francisco, CA), a reversible
tyrosine kinase inhibitor that selectively blocks the epidermal
growth factor receptor (EGFR), is commonly used as a ﬁrst line
chemotherapy agent for non-small cell lung cancer (NSCLC) and
pancreatic cancer. Trichomegaly, dry eyes and delayed corneal
wound healing1e3 are noted with the use of erlotinib.
We report a case of erlotinib-associated severe recalcitrant
bilateral keratouveitis after uneventful corneal ethyl-
enediaminetetraacetic acid (EDTA) chelation in a patient with
NSCLC. Discontinuation of erlotinib led to complete resolution of
both keratitis and uveitis.ology, University of Florida,
cksonville, FL, 32209, United
Inc. This is an open access article u2. Case report
An elderly patient, in 7th decade of life presented with band
keratopathy of undetermined etiology in both eyes, associated with
annoying foreign body sensation and constant tearing. The patient
was on oral Erlotinib treatment 150 mg daily for 1 year for NSCLC
status post radiation therapy. Patient’s other medical problems
included biopsy conﬁrmed sarcoidosis, chronic obstructive
pulmonary disease, hypertension, type II diabetes mellitus, osteo-
arthritis and gastroesophageal reﬂux disease. The patient was
pseudophakic in both eyes with end-stage glaucoma. The patient’s
best corrected visual acuity (BCVA) was 20/50 in the right eye and
light perception in the left. Intraocular pressure was 10 mmHg
in the right and 5 mmHg in the left. Slit lamp biomicroscopy
examination (SLE) showed bilateral interpalpebral band
keratopathy.
Under topical anesthesia, EDTA was applied after removal of
corneal epithelia; calcium plaques were scraped off uneventfully innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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topical vigamox and 1% pred forte QID for postoperative care.
Four days after surgery, the patient presented with severe pain
in both eyes. BCVA was hand motion at face in the right eye and
light perception in the left. SLE revealed 5 mm  7 mm epithelial
defect with clear margins in the right eye and 6  7 mm
epithelial defect with thick central corneal inﬁltrate in the left.
Hypopyon was noticed in both eyes (right 1 mm, left <1 mm), and
intense inﬂammation obscured the details of anterior segment.
Corneal scraping was performed on both eyes and send for
microbiological evaluation (gram staining, KOH slide evaluation
and cultures). Ultrasound did not reveal vitritis in either eye.
Intense antibiotic treatment was initiated (topical fortiﬁed van-
comycin and tobramycin alternating every hour and oral dox-
ycyclin 100 mg BID PO). Concurrent erlotinib use was of concern
but oral erlotinib could not be discontinued per recommendation
of oncology services.
One week later, the left eye developed new satellite corneal
inﬁltrates and thinning of the stroma in the central area despite
antibiotic therapy (Fig. 1AeB). Culture reports from the corneal
scraping were negative. Non-healing corneal epithelial defect, as
well as persistent hypopyon in the anterior chamber were still
noted three weeks after the surgery in both eyes despite intensive
antibiotic and antifungal treatment (Fig. 2AeB).
After further discussion with the oncology services, oral erloti-
nib was discontinued. Subsequently discontinuation of erlotinib,
lead to resolution of keratitis, as well as hypopyon resolved in both
eyes, in one week. BCVA improved to 20/50 in the right eye and
remained light perception in the left (Fig. 3AeB).Fig. 1. Post op day 15. (A) The right eye showed corneal epithelial defect measuring
about 6  4 mm without associated corneal inﬁltrates. (B) The left eye presented with
central corneal inﬁltrate, stromal thinning and multiple small satellite inﬁltrates
around the central ulcer.
Fig. 2. Post op day 21. (A) Anterior chamber hypopyonwas noted in the right eye with
persistent corneal epithelial defect but no corneal inﬁltrates. (B) The left eye presented
with dense central corneal inﬁltrates and stromal thinning.3. Discussion
Erlotinib (Tarceva), a reversible tyrosine kinase inhibitor (se-
lective blocker of EGFR), is commonly used as a ﬁrst line chemo-
therapy agent for NSCLC.4 However, erlotinib induces ocular
complications including trichomegaly and delayed corneal wound
healing.1 Erlotinib violates ocular immune status, and induces in-
ﬂammatory anterior uveitis.5e7 It may also suppress local immunity
and facilitate ocular infection through suppression of human beta
defensin 2 and 3, natural defense against Staphylococcus epi-
dermidis.8 In addition, erlotinib impairs T-cell-mediated immune
response both in vitro and in vivo through inhibition of T cell
proliferation and activation via down-regulation of the c-Raf/ERK
cascade and Akt signaling pathway.9 Rao V et al.10 reported a case of
bilateral acquired toxoplasmic retinochoroiditis during erlotinib
therapy. Erlotinib inhibits epidermal growth factor receptorein-
duced activation of STAT, which impairs host resistance to Toxo-
plasma gondii.10 The clinical course was atypical in our case and
despite two weeks of intensive topical antibiotics treatment,
keratitis was recalcitrant in both eyes. The patient developed
recurrent corneal inﬁltrates with severe anterior uveitis, which was
an atypical clinical presentation for infectious keratouveitis. We
believe systemic use of erlotinib impaired local immunity and
facilitated keratitis in both eyes. In addition, it exacerbated uveitis
in the right eye through alteration of immune status. Discontinu-
ation of erlotinib resulted in complete clinical recovery for both
eyes.
Fig. 3. Post op day 35. (A) The right eye showed healed corneal epithelial defect with
trace stromal scar in the central area. (B) The left eye had dense central stromal scar
with surrounding neovascularization.
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In summary, systemic use of erlotinib suppresses local immu-
nity, facilitates infection and enhances inﬂammatory reaction in theeye. Clinicians should be cautious and plan any ocular interven-
tional treatment in collaboration with oncology team to prevent
adverse outcomes.4.1. Informed consent
Not obtained. Personal identifying information was removed
from this report as informed consent to publish such information
was not obtained.Conﬂict of interest
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